Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect oractions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.

Biotechnology

Health Care

Life Sciences

Therapeutics

Enterome

Belichard Pierre

Lucie Rouch

Joao G. Magalhaes

Pierre Sahakian

Marie-Laure Bouttier

Joel Richard, PhD, HDR

Jean-Michel Paillarse

Jan Fagerberg

Christelle Dumoussaud

The Research and Development team at Enterome focuses on the discovery, design, and advancement of small protein and peptide drug candidates that modulate the immune system to fight cancer. This team conducts preclinical and clinical studies, analyzes data to optimize therapeutic efficacy, identifies biomarkers, and collaborates across disciplines to translate innovative research into viable treatments, currently targeting hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Research and Development

Leadership Team

Clinical Development

Research and Development

About

Team members

Other teams at Enterome

Leadership Team

Clinical Development